Search
Chemomab Therapeutics Ltd
CMMBAdd to Watchlist
2.270USD
+0.550+31.98%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
65.38MMarket Cap
13.03P/E TTM
More Details of Chemomab Therapeutics Ltd Company
Chemomab Therapeutics Ltd (formerly known as Anchiano Therapeutics Ltd) is a Israel-based clinical-stage biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of fibrotic and inflammatory diseases with high unmet medical need among others. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltd Info
Ticker SymbolCMMB
Company nameChemomab Therapeutics Ltd
IPO dateAug 14, 2012
CEOMor (Adi)
Number of employees16
Security typeDepository Receipt
Fiscal year-endAug 14
AddressKiryat Atidim, Building 7
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code6158002
Phone972773310156
Websitehttps://www.chemomab.com/
Ticker SymbolCMMB
IPO dateAug 14, 2012
CEOMor (Adi)
Company Executives of Chemomab Therapeutics Ltd
Name
Name/Position
Position
Shareholding
Change
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
14.48K
+95.59%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Chemomab Therapeutics Ltd?
The top five shareholders of Chemomab Therapeutics Ltd are: Ms. Sigal Fattal, CPA
How many institutions hold shares of Chemomab Therapeutics Ltd (CMMB)?
As of 2026Q1, 33 institutions hold shares of Chemomab Therapeutics Ltd, with a combined market value of approximately 402.96K, accounting for 5.60% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -450971.00.